Prostanoids receptors signaling in different diseases/cancers progression

References

• Shindou H, Hishikawa D, Harayama T, et al. Recent progress on acyl CoA: lysophospholipid acyltransferase research. J Lipid Res 2009;50:S46–51
   PubMed Web of Science ®Google Scholar
• Capra V, Back M, Barbieri SS, et al. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 2012preprint:1–75pp [Epub ahead of print]
   Google Scholar
• Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181–193
   PubMed Web of Science ®Google Scholar
• Menter DG, DuBois RN. Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol 2012;2012: 723419
   Google Scholar
• Takeuchi K, Kato S, Amagase K. Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity. J Pharmacol Sci 2010;3:248–61
   Google Scholar
• Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends. Immunol 2002;23:144–50
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Asano K, Nakajima T, et al. Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther 2005;312:954–60
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6:313–25
   PubMed Web of Science ®Google Scholar
• Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255–61
   PubMed Web of Science ®Google Scholar
• Gosset P, Bureau F, Angeli V, et al. Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naïve Th cells. J Immunol 2003;170:4943–52
   PubMed Web of Science ®Google Scholar
• Nantel F, Fong C, Lamontagne S, et al. Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa. Prostaglandins Other Lipid Mediat 2004;73:87–101
   PubMed Web of Science ®Google Scholar
• Wright DH, Ford-Hutchinson AW, Chadee K, et al. The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. Br J Pharmacol 2000;31:1537–45
   Google Scholar
• Moreland RB, Nehra A, Kim NN, et al. Expression of functional prostaglandin D(DP) receptors in human corpus cavernosum smooth muscle. Int J Impot Res 2002;14:446–52
   PubMed Web of Science ®Google Scholar
• Chen Y, Perussia B, Campbell KS. Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J Immunol 2007;179:2766–73
   Google Scholar
• Mohri I, Taniike M, Taniguchi H, et al. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J Neurosci 2006;26:4383–93
   PubMed Web of Science ®Google Scholar
• Bousquet J. Allergic rhinitis and its impact on asthma (ARIA). Clin Exp Allergy Rev 2003;3:43–5
   Google Scholar
• Johnson JR, Wiley RE, Fattouh R, et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care Med 2004;169:378–85
   PubMed Web of Science ®Google Scholar
• Arima M, Fukuda T. Prostaglandin D2 and TH2 inflammation in the pathogenesis of bronchial asthma. Korean J Intern Med 2011;26:8–18
   PubMedGoogle Scholar
• Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011;183:299–309
   PubMed Web of Science ®Google Scholar
• Kabashima K, Narumiya S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:187–94
   PubMed Web of Science ®Google Scholar
• Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000;287:2013–17
   PubMed Web of Science ®Google Scholar
• Matsuoka T, Narumiya S. Prostaglandin receptor signaling in disease. Sci World J 2007;7:1329–47
   Google Scholar
• Giles H, Leff P, Bolofo ML, et al. The classification of prostaglandin DP receptors in platelets and vasculature using BWA868C, a novel, selective and potent competitive antagonist. Br J Pharmacol 1989;96:291–300
   PubMed Web of Science ®Google Scholar
• Arimura A, Yasui K, Kishino J, et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 2001;29:411–19
   Google Scholar
• Hirano Y, Shichijo M, Ikeda M, et al. Prostanoid DP receptor antagonists suppress symptomatic asthma-like manifestation by distinct actions from a glucocorticoid in rats. Eur J Pharmacol 2011;666:233–41
   PubMed Web of Science ®Google Scholar
• Norman P. DP2 receptor antagonists in development. Expert Opin Invest Drugs 2010;19:947–61
   PubMed Web of Science ®Google Scholar
• Hirai H, Tanaka K, Takano S, et al. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 2002;168:981–5
   PubMed Web of Science ®Google Scholar
• Böhm E, Sturm GJ, Weiglhofer I, et al. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem 2004;279:7663–70
   Google Scholar
• Sandham DA, Adcock C, Bala K, et al. 7-Azaindole-3-acetic acid derivatives: potent and selective CRTH2 receptor antagonists. Bioorg Med Chem Lett 2009;19:4794–8
   PubMed Web of Science ®Google Scholar
• Sandham DA, Aldcroft C, Baettig U, et al. 2-Cycloalkyl phenoxyacetic acid CRTH2 receptor antagonists. Bioorg Med Chem Lett 2007;17:4347–50
   PubMed Web of Science ®Google Scholar
• Liu J, Wang Y, Sun Y, et al. Tetrahydroquinoline derivatives as CRTH2 antagonists. Bioorg Med Chem Lett 2009;19:6840–4
   PubMed Web of Science ®Google Scholar
• Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009;158:104–45
   PubMed Web of Science ®Google Scholar
• Schuligoi R, Sturm E, Luschnig P, et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 2010;85:372–82
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8–16
   PubMed Web of Science ®Google Scholar
• Okuda, M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann. Allergy Asthma Immunol 2003;91:288–96
   PubMed Web of Science ®Google Scholar
• Stebbins KJ, Broadhead AR, Correa LD, et al. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010;638:142–9
   PubMed Web of Science ®Google Scholar
• Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812–17
   PubMed Web of Science ®Google Scholar
• Nomiya R, Okano M, Fujiwara T, et al. CRTH2 plays an essential role in the pathophysiology of Cry j 1-induced pollinosis in mice. J Immunol 2008;180:5680–8
   Google Scholar
• Xavier RJ, Podolsky D K. Unravelling the pathogenesis of in flammatory bowel disease. Nature 2007;448:427–34
   PubMed Web of Science ®Google Scholar
• Zamuner SR, Bak AW, Devchand PR, et al. Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am J Pathol 2005;167:1293–300
   Google Scholar
• Kim N, Luster AD. Regulation of immune cells by eicosanoid receptors. Scientific World J 2007;7:1307–28
   Google Scholar
• Zamuner SR, Warrier N, Buret AG, et al. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 2003;52:1714–20
   PubMed Web of Science ®Google Scholar
• Kariya S, Okano M, Aoji K, et al. Role of macrophage migration inhibitory factor in otitis media with effusion in adults. Clin Diagn Lab Immunol 2003;10:417–22
   PubMedGoogle Scholar
• Smirnova MG, Kiselev SL, Gnuchev NV, et al. Role of the pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6 and interleukin-8 in the pathogenesis of the otitis media with effusion. Eur Cytokine Network 2002;13:161–72
   PubMed Web of Science ®Google Scholar
• Harada T, Juhn SK, Kim Y, et al. Arachidonic acid metabolism by isolated and cultured middle ear epithelial cells from the chinchilla. Eur Arch Otorhinolaryngol 1993;250:220–3
   Google Scholar
• Eguchi M, Kariya S, Okano M, et al. Lipopolysaccharide induces proinflammatory cytokines and chemokines in experimental otitis media through the prostaglandin D2 receptor (DP)-dependent pathway. Clin Exper Immunol 2010;163:260–9
   Google Scholar
• Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:13180–5
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–210
   PubMed Web of Science ®Google Scholar
• Brule S, Wallemme L, Uwambayinema F, et al. The D prostanoid receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] inhibits fibroblast proliferation and bleomycin-induced lung fibrosis in mice. J Pharmacol Exper Therap 2010;335:472–9
   Google Scholar
• Shimura C, Satoh T, Igawa K, et al. Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin. Am J Pathol 2011;176:227–37
   Google Scholar
• Monneret G, Gravel S, Diamond M, et al. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001;98:1942–8
   PubMed Web of Science ®Google Scholar
• Nakahigashi K, Hiromi D, Otsuka A, et al. PGD2 induces eotaxin-3 via PPARγ from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol 2012;129:536–43
   Google Scholar
• Lubberts E, Joosten LA, van den Bersselaar L, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999;163:4546–56
   PubMed Web of Science ®Google Scholar
• Maicas N, Ibanez L, Alcaraz MJ, et al. Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis. Amer College Rheumatol 2012;64:130–40
   Google Scholar
• Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798–801
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94–114
   PubMed Web of Science ®Google Scholar
• Papaliodis D, Boucher W, Kempuraj D, et al. Niacin-induced “flush” involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther 2008;327:665–72
   PubMed Web of Science ®Google Scholar
• Trivedi SG, Newson J, Rajakariar R, et al. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. PNAS 2006;103:5179–84
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Prac 2009;63:1369–77
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne C. What’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009;20:467–76
   PubMed Web of Science ®Google Scholar
• Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009;5:901–8
   PubMedGoogle Scholar
• Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007;59:207–24
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613–7
   PubMed Web of Science ®Google Scholar
• Dey I, Lejeune M, Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 2006;149:611–23
   PubMed Web of Science ®Google Scholar
• Rodríguez-Lagunas MJ, Martín-Venegas R, Moreno JJ, et al. PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers. Am J Physiol Cell Physiol 2010;299:C324–34
   Google Scholar
• Francesco P, Schena LG. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16:S30–3
   Google Scholar
• Hirasawa Y, Sakai T, Ito M, et al. Advanced-glycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway. Eur J Pharmacol 2011;672:159–68
   PubMed Web of Science ®Google Scholar
• Urdyke P, Rendshorstwj A. EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 2000;279:F755–64
   Google Scholar
• Makino H, Tanaka I, Mukoyama M, et al. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 2002;13:1757–65
   PubMed Web of Science ®Google Scholar
• Suganami T, Tanaka I, Mukoyama M, et al. Altered growth response to prostaglandin E2 and its receptor signaling in mesangial cells from stroke-prone spontaneously hypertensive rats. J Hypertens 2001;19:1095–103
   Google Scholar
• Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518–27
   PubMed Web of Science ®Google Scholar
• Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007;59:247–58
   PubMed Web of Science ®Google Scholar
• Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004;31:64–73
   PubMed Web of Science ®Google Scholar
• Wang D, Buchanan FG, Wang H, et al. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005;65:1822–9
   PubMed Web of Science ®Google Scholar
• Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181–93
   PubMed Web of Science ®Google Scholar
• Kim S-H, Park Y-Y, Kim S-W, et al. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res 2011;71:7010–20
   Google Scholar
• Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005;115:118–28
   PubMed Web of Science ®Google Scholar
• De Mattei M, Varani K, Masieri FF, et al. Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts. Osteoarthr Cartilage 2009;17:252–62
   PubMed Web of Science ®Google Scholar
• Kunisch E, Jansen A, Kojima F, et al. Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-α on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol 2009;183:1328–36
   Google Scholar
• Akangi J, Nozaki T, Satoh M, et al. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006;6:383–94
   Google Scholar
• Nozaki TS, Ito H, Mitomi H, et al. Endogenous prostaglandin E2 inhibits aberrant overgrowth of rheumatoid synovial tissue and the development of osteoclast activity through EP4 receptor. Arthr Rheumat 2011;63:2595–605
   Google Scholar
• Miyaura C, Inada M, Suzawa T, et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000;275:19819–23
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–55
   PubMed Web of Science ®Google Scholar
• Pavord ID, Wong CS, Williams J, et al. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 1993;148:87–90
   PubMed Web of Science ®Google Scholar
• Fortner CN, Breyer RM, Paul RJ. EP2 receptors mediate airway relaxation to substance P, ATP, and PGE2. Am J Physiol Lung Cell Mol Physiol 2001;281:L469–74
   PubMed Web of Science ®Google Scholar
• Buckley J, Birrell MA, Maher SA, et al. EP4 receptor as a new target for bronchodilator therapy. Thorax 2011;66:1029–35
   PubMed Web of Science ®Google Scholar
• Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression with the deletion of reference 87 please adjust the numbers of the intext citations accordingly in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003;63:2330–4
   PubMed Web of Science ®Google Scholar
• Spinella F, Rosano L, Di Castro V, et al. Endothelin 1-induced prostaglandinE2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 2004;279:46700–5
   PubMed Web of Science ®Google Scholar
• Amano H, Hayashi J, Endo H, et al. Host prostaglandin E2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197:221–32
   PubMed Web of Science ®Google Scholar
• Alfranca A, Lopez-Oliva JM, Genis L, et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood 2008;112:1120–8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Daaka Y. PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood 2011;118:5355–64
   PubMed Web of Science ®Google Scholar
• Eley BM, Cox SW. Proteolytic and hydrolytic enzymes from putative periodontal pathogens: characterization, molecular genetics, effects on host defenses and tissues and detection in gingival crevice fluid. Periodontol 2003;31:105–24
   Google Scholar
• Noguchi K, Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease. Periodontol 2007;43:85–101
   Google Scholar
• Oka H, Miyauchi M, Sakamoto K, et al. PGE2 activates cementoclastogenesis by cementoblasts via EP4. J Dent Res 2007;86:974–9
   Google Scholar
• Guan SM, Shu L, Fu SM, et al. Prevotella intermedia upregulates MMP-1 and MMP-8 expression in human periodontal ligament cells. FEMS Microbiol Lett 2009;299:214–22
   PubMed Web of Science ®Google Scholar
• Cirillo R, Tos EG, Page P, et al. Arrest of preterm labor in rat and mouse by an oral and selective nonprostanoid antagonist of the prostaglandin F2α receptor(FP). Am J Obstet Gynecol 2007;197:e1–9
   Google Scholar
• Sales KJ, Boddy SC, Williams AR, et al. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 2007;148:3635–44
   Google Scholar
• Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-newlight through old windows. J Steroid Biochem Mol Biol 2008;108:221–9
   PubMed Web of Science ®Google Scholar
• Jabbour HN, Sales KJ, Boddy SC, et al. A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2αsynthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology 2005;146:4657–64
   Google Scholar
• Sales KJ, Boddy SC, Jabbour HN. F-Prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene 2008;27:2466–77
   Google Scholar
• Sales KJ, Grant V, Cook IH, et al. Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2α-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol 2010;176:435–5
   PubMed Web of Science ®Google Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53:S107–20
   PubMed Web of Science ®Google Scholar
• Hutchinson AJ, Coons SC, Chou C-L, et al. Induction of angiogenic immediate early genes by activation of FP prostanoid receptors in cultured human ciliary smooth muscle cells. Curr Eye Res 2010;35:408–18
   PubMed Web of Science ®Google Scholar
• Swales J. Textbook of hypertension. Boston: Blackwell Scientific; 1994
   Google Scholar
• Yu Y, Lucitt MB, Stubbe J, et al. Prostaglandin F2α elevates blood pressure and promotes atherosclerosis. PNAS 2009;106:7985–90
   PubMed Web of Science ®Google Scholar
• Nussberger J, Aubert JF, Bouzourene K, et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008;51:1306–11
   PubMed Web of Science ®Google Scholar
• Slater DM, Zervou S, Thornton S. Prostaglandins and prostanoid receptors in human pregnancy and parturition. J Soc Gynecol Invest 2002;9:118–24
   PubMedGoogle Scholar
• Hirst JJ, Parkington HC, Young IR, et al. Delay of preterm birth in sheep by THG113.31, a prostaglandin F2α receptor antagonist. Am J Obstet Gynecol 2005;193:256–66
   PubMed Web of Science ®Google Scholar
• Bogatcheva NV, Sergeeva MG, Dudek SM, et al. Arachidonic acid cascade in endothelial pathobiology. Microvasc Res 2005;69:107–27
   PubMed Web of Science ®Google Scholar
• Kuo C-H, Lin C-H, Yang S-N, et al. Effect of PGI2 analogs on cytokine expression in human myeloid dendritic cells via epigenetic regulation. Mol Med 2012;18:433–44
   Google Scholar
• Idzko M, Hammad H, van Nimwegen M, et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 2007;117:464–72
   PubMed Web of Science ®Google Scholar
• Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007;28:551–8
   PubMed Web of Science ®Google Scholar
• Hatae T, Wada M, Yokoyama C, et al. Prostacyclin-dependent apoptosis mediated by PPARd. J Biol Chem 2001;276:46260–7
   PubMed Web of Science ®Google Scholar
• Dunn MJ. Prostaglandin I2 and the kidney. Arch Mal Coeur 1989;82:27–31
   Google Scholar
• Dwyer-Nield LD, Srebernak MC, Barrett BS, et al. Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis 2005;26:1196–206
   PubMed Web of Science ®Google Scholar
• Iniguez MA, Cacheiro-Llaguno C, Cuesta N, et al. Prostanoid function and cardiovascular disease. Arch Physiol Biochem 2008;114:201–9
   PubMedGoogle Scholar
• Boswell MG, Zhou W, Newcomb DC, et al. PGI2 as a regulator of CD4+ subset differentiation and function. Prostaglandins Other Lipid Mediat 2011;96:21–6
   PubMed Web of Science ®Google Scholar
• Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S–61S
   PubMed Web of Science ®Google Scholar
• Nakahata, N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Therap 2008;118:18–35
   PubMed Web of Science ®Google Scholar
• Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005;48:1439–44
   Google Scholar
• Wright WS, Messina JE, Harris NR. Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist. Exper Eye Res 2009;88:106–112
   Google Scholar
• United States Cancer Statistics: 1999–2007. Incidence and mortality web-based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. U.S.C.S.W. Group; 2010
   Google Scholar
• Nie D, Che M, Zacharek A, et al. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Amer J Pathol 2004;164:429–39
   PubMed Web of Science ®Google Scholar
• Watkins, G, Douglas-Jones A, Mansel RE, et al. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int Sem Surg Oncol 2005;2:23
   Google Scholar
• Wei J, Yan W, Li X, et al. Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer 2010;69:26–32
   Google Scholar
• Cathcart MC, Gately K, Cummins R, et al. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol Cancer 2011;10:25
   Google Scholar
• McAfee AJ, McSorley EM, Cuskelly GJ, et al. Red meat consumption: an overview of the risks and benefits. Meat Sci 2010;84:1–13
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Therapy 2006;6:1087–104
   PubMed Web of Science ®Google Scholar
• Giese A, Hagel C, Kim EL, et al. Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-Oncol 1999;1:3–13
   PubMedGoogle Scholar
• Moussa O, Riker JM, Klein J, et al. Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 2008;27:55–62
   PubMed Web of Science ®Google Scholar
• Moussa O, Ashton AW, Fraig M, et al. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res 2008;68:4097–104
   Google Scholar
• Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004;117:3–32
   PubMedGoogle Scholar
• Miyamoto M, Ohno M, Yamada N, et al. TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood. Thromb Haemost 2010;104:788–95
   Google Scholar
• Pal S, Wu J, Murray JK, et al. An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis. J Cell Biol 2006;174:1047–58
   Google Scholar
• Yoshimoto A, Kasahara K, Kawashima A, et al. Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol Rep 2005;13:1049–57
   Google Scholar